Is obesity a predictor for lack of response to treatment in psoriatic arthritis? A systematic review

Reumatol Clin (Engl Ed). 2021 May;17(5):268-278. doi: 10.1016/j.reuma.2019.06.003. Epub 2019 Nov 8.
[Article in English, Spanish]

Abstract

Objectives: To update the study of the association between obesity and treatment response in psoriatic arthritis.

Methods: Updating a systematic review of clinical trials, prospective or retrospective longitudinal studies and case-control studies in psoriatic arthritis in which obesity was assessed as a predictor of efficacy or toxicity. Risks of bias were assessed with validated scales. A meta-analysis of the results of studies with similar outcome variables and weight measurements was performed.

Results: Twenty-one studies were included (6 review of clinical trials, 6 longitudinal studies, 7 registers and one case-control studie), with moderate quality. The risk of achieving an ACR20 response if weight≥100kg was estimated at OR=1.42 (1-2.08) and that of withdrawing treatment in an OR of 1.60 (95% CI: 1.34 - 1.92).

Conclusions: There seems to be a greater risk of withdrawal of treatment due to inefficacy and difficulty in achieving remission in patients with psoriatic arthritis if they are obese.

Keywords: Artritis psoriásica; Factores predictivos; Obesidad; Obesity; Predictive factors; Psoriatic arthritis; Respuesta terapéutica; Revisión sistemática; Systematic review; Therapeutic response; Toxicidad; Toxicity.